Third-Line Treatments in Colorectal Cancer - priME Oncology
Expert Review
Expert Review

Third-Line Treatments in Colorectal Cancer

What Every Nurse Needs to Know About Managing Adverse Events

Not a member of My prIME? Join now for instant access.

This highly engaging, mixed-media educational activity is designed specifically to address the needs of nurses who manage patients with metastatic colorectal cancer. Hear from the experts as they discuss safety issues related to third-line treatments and review optimal communication strategies for educating patients about treatment-related adverse events (TEAEs). These communication techniques are then modeled in an animated, role-play exercise. This activity also includes interactive components and valuable downloadable tools for nurses to use with their patients and colleagues.

Interactive Presentation

Interactive Presentation

CE

CE

Estimated time to complete activity: 1.0 hour

Animation

Animation

Patient Education

Patient Education

Release Date

Release Date

May 17, 2018

Expiration Date

May 17, 2019

  • Carolyn Grande, CRNP, AOCNPThe Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Megan Price, MSN, RN, NP-CUCLA Hematology/Oncology
    Santa Monica, California, United States
  • Epidemiology of metastatic colorectal cancer and current medical therapies in the first-, second-, and third-line settings
  • Safety issues with third-line treatment options and how they are managed
  • Best practices for communicating with patients about medication side effects

This educational activity is designed for registered nurses and advanced-practice registered nurses who are active in the treatment/management of patients with colorectal cancer.

After successful completion of this educational activity, participants should be able to:

  • Analyze the available agents used in the third-line treatment of metastatic colorectal cancer
  • Assess common TEAEs associated with agents used in the third-line treatment of metastatic colorectal cancer
  • Describe best practices that can foster improved nurse-patient discussions/communication that can address, educate on, and manage potential TEAEs associated with third-line treatments for metastatic colorectal cancer

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

Third-Line Treatments in Colorectal Cancer - prIME OncologyIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Postgraduate Institute for Medicine (PIM) has established the maximum number of hours awarded for this Continuing Nursing Education activity to be 1.0 contact hour.

Designated for 0.2 contact hour of pharmacotherapy credit for advanced practice registered nurses.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Oncologic Emergencies, Professional Practice, Symptom Management, and Treatment.

Provider

This activity is provided by prIME Oncology and Postgraduate Institute for Medicine.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CE credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CE activity will be recorded in prIME Oncology’s database. However, upon request, your CE credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carolyn Grande has disclosed that she has received consulting fees from Bayer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Megan Price has disclosed that she has been a speaker for Taiho Oncology. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.